OncLive® On Air

OncLive® On Air
  • 4.3 (22)
  • Health & Fitness
  • Updated Semiweekly

In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.

  1. 1d ago

    Current Approaches and Future Directions for Early-Stage TNBC

    Highlights from the PER® CME activity "Current Approaches and Future Directions for Early-Stage TNBC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below. In this podcast, experts Nour Abuhadra, MD, and Antonio Giordano, MD, PhD, discuss the emerging role of antibody-drug conjugates (ADCs) in early-stage triple-negative breast cancer (TNBC) and the practice implications of ongoing post-neoadjuvant trials. Earn CME credit by completing the full accredited activity (available through July 31, 2027): https://www.gotoper.com/courses/current-approaches-and-future-directions-for-early-stage-tnbcThis podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from Gilead Sciences, Inc. This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

    Current Approaches and Future Directions for Early-Stage TNBC

  2. 5d ago

    Non–Small Cell Lung Cancer 2026 UPDATE

    Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago. In this episode, OncLive On Air® partnered with Two Onc Docs to deliver a comprehensive, board-focused review of early-stage and locally advanced non–small cell lung cancer (NSCLC) for 2026, reflecting recent shifts in staging and perioperative therapy. The discussion began with histology, distinguishing adenocarcinoma (positive for TTF-1 and CK7) from squamous cell carcinoma (positive for p63 and p40). Turning to staging, Drs Armstrong and Tawagi emphasized the 9th edition of the lung cancer TNM staging system, noting that T categories are unchanged but N2 is now split into N2a and N2b, and M1c is now split into M1c1 and M1c2. They also stressed the importance of biomarker testing for PD-L1, EGFR, ALK, and RET. Regarding treatment, they explained that stage IA disease warrants surgery or stereotactic body radiation therapy without systemic therapy. In resectable disease that is 4 cm or larger or node-positive disease, driver mutations guide management: osimertinib (Tagrisso) for EGFR-mutated disease, alectinib (Alecensa) for ALK-positive disease, and selpercatinib (Retevmo) for RET-mutated disease, with immunotherapy avoided in EGFR-mutated or ALK-positive tumors. For driver-negative disease, they reviewed 4 category 1 regimens, including neoadjuvant nivolumab (Opdivo) and perioperative pembrolizumab (Keytruda) or nivolumab, cautioning against switching agents in the middle of a treatment course. Drs Armstrong and Tawagi then addressed adjuvant immunotherapy, unresectable stage III disease management with concurrent chemoradiation followed by consolidative durvalumab (Imfinzi) or osimertinib, surgical candidacy, adjuvant chemotherapy regimens, postoperative radiation, and special circumstances, including superior sulcus tumors.

    Non–Small Cell Lung Cancer 2026 UPDATE

  3. Aug 28

    FDA Approval Insights: Integrating RP1 Plus Nivolumab Into Post–PD-1 Melanoma Practice: With Michael K. Wong, MD, PhD, FRPC

    In today's episode, we spoke with Michael K. Wong, MD, PhD, FRPC. Dr Wong is a physician at Roswell Park Comprehensive Cancer Center in Buffalo, New York. In our exclusive interview, Dr Wong discussed the significance of the FDA’s accelerated approval of vusolimogene oderparepvec-wtpg (Tudriqev; RP1) in combination with nivolumab (Opdivo) for adult patients with unresectable advanced cutaneous melanoma whose disease progressed on a prior PD-1–blocking antibody–based regimen. He noted that this approval followed a lengthy regulatory trajectory, including two prior complete response letters, before a third biologics license application was accepted in June 2026 and a positive advisory committee vote paved the way for approval. Dr Wong contextualized the evidentiary basis for the approval, drawing on data from the single-arm, phase 1/2 IGNYTE trial (NCT03767348), in which the efficacy-evaluable population achieved an objective response rate of 24.2% (95% CI, 15.8%-34.3%) and a median duration of response of 14.1 months (95% CI, 10.7-not reached). He emphasized that the trial enrolled a genuinely high-risk population, including patients with elevated lactate dehydrogenase, more than 55% with PD-L1–negative tumors by immunohistochemistry, 44% who had failed prior ipilimumab (Yervoy) plus nivolumab, and 66% with primary resistance to anti–PD-1 therapy, making the results clinically meaningful in the context of a setting where no robust options previously existed.   He also addressed the distinction between RP1 and talimogene laherparepvec (Imlygic), the prior herpes-based oncolytic agent, explaining that RP1 is a fundamentally reengineered particle with distinct genetic modifications, enhanced oncolytic activity, and an expanded injection approach that includes visceral lesions such as those in the liver and lung. From an operational standpoint, Dr Wong outlined key considerations for community and academic practices looking to integrate RP1, including room setup, pharmacy handling of live agents, personal protective equipment protocols, and the importance of partnering with interventional radiology to inject a diversity of lesions across nodal basins for optimal response. Finally, Dr Wong positioned RP1 plus nivolumab within the broader post–PD-1 treatment landscape alongside tumor-infiltrating lymphocyte (TIL) therapy, noting that although both options now occupy this space, RP1 plus nivolumab offers a more broadly accessible treatment approach given the logistical demands of TIL therapy.

    FDA Approval Insights: Integrating RP1 Plus Nivolumab Into Post–PD-1 Melanoma Practice: With Michael K. Wong, MD, PhD, FRPC

  4. Aug 28

    Immunotherapy Decision-Making in CSCC Sits at the Intersection of Efficacy and Comorbidity: With Eric D. Whitman, MD; and Francis Paul Worden, MD

    Eric D. Whitman, MD, and Francis Paul Worden, MD, discuss the integration of immunotherapy into the cutaneous squamous cell carcinoma (CSCC) treatment paradigm and key considerations for navigating treatment selection for this patient population. The pair also highlight strategies to maximize efficacy and minimize toxicity with immunotherapy-based approaches.

    Immunotherapy Decision-Making in CSCC Sits at the Intersection of Efficacy and Comorbidity: With Eric D. Whitman, MD; and Francis Paul Worden, MD

  5. Aug 27

    FDA Approval Insights: Iberdomide-Based Therapy Adds Another Option for R/R Myeloma: With Sagar Lonial, MD, FACP, FASCO

    In today’s episode, we welcomed Sagar Lonial, MD, FACP, FASCO, to discuss the significance of the August 2026 FDA accelerated approval of iberdomide (Zenbexus) plus daratumumab and hyaluronidase-fihj (Darzalex Faspro) and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. Dr Lonial is a professor and chair of the Department of Hematology and Medical Oncology at Emory University School of Medicine, as well as chief medical officer at Winship Cancer Institute of Emory University in Atlanta, Georgia.  In the exclusive interview, Dr Lonial discussed the significance of the first approval of a CELMoD-based therapy for patients with multiple myeloma, detailed the key findings from the phase 3 EXCALIBER-RRMM trial (NCT04975997) that supported the regulatory decision, and expanded on how this combination regimen fits into the early relapse treatment paradigm.

    FDA Approval Insights: Iberdomide-Based Therapy Adds Another Option for R/R Myeloma: With Sagar Lonial, MD, FACP, FASCO

  6. Aug 24

    𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

    Highlights from the PER® CME activity "MET Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below. In this podcast, experts Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; and Anne S. Tsao, MD, MBA, discuss diagnostic and treatment strategies for patients with MET-altered non–small cell lung cancer. Earn CME credit by completing the full accredited activity (available through September 19, 2026): https://www.gotoper.com/courses/met-alterations-in-nsclc-applying-diagnostic-advances-and-targeted-therapies-in-a-new-era-of-treatment-vdpvThis podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from AbbVie, Inc. This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

    𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

  7. Aug 20

    Pancreatic Cancer Treatment Advances Call for a Renewed Focus on the Role of Liposomal Irinotecan: With Jennifer B. Valerin, MD, PhD

    In today’s episode, we spoke with Jennifer B. Valerin, MD, PhD. Dr Valerin is an assistant professor in the Divisions of Hematology and Oncology and Medicine at the University of California, Irvine School of Medicine. In our exclusive interview, Dr Valerin discussed the clinical role of liposomal irinotecan (Onivyde) in pancreatic cancer management, factors influencing the decision to use liposomal irinotecan in practice, and developments she is excited to see as the pancreatic cancer landscape is shifting toward highly targeted and combination approaches.

    Pancreatic Cancer Treatment Advances Call for a Renewed Focus on the Role of Liposomal Irinotecan: With Jennifer B. Valerin, MD, PhD

  8. Aug 17

    Key Considerations for Health Equity and Patient-Centered Care in TNBC

    Highlights from the PER® CME activity "Key Considerations for Health Equity and Patient-Centered Care in TNBC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below. In this podcast, experts Aditya Bardia, MD, MPH, FASCO, and Kathryn E. Post, PhD, ANP-BC, discuss key drivers of disparities in outcomes for triple-negative breast cancer and strategies for patient-centered communication, from shared decision-making to managing treatment-related toxicity. Earn CME credit by completing the full accredited activity (available through July 31, 2027): https://www.gotoper.com/courses/key-considerations-for-health-equity-and-patient-centered-care-in-tnbcThis podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from Gilead Sciences, Inc. This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

    Key Considerations for Health Equity and Patient-Centered Care in TNBC
See All (500)

4.3
out of 5
22 Ratings

About

In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.

Information

  • Creator
    OncLive® On Air
  • Years Active
    2018 - 2026
  • Episodes
    500
  • Rating
    Clean
  • Show Website
    OncLive® On Air

You Might Also Like